CN1856310A - 喹唑啉钾通道抑制剂 - Google Patents

喹唑啉钾通道抑制剂 Download PDF

Info

Publication number
CN1856310A
CN1856310A CNA2004800274716A CN200480027471A CN1856310A CN 1856310 A CN1856310 A CN 1856310A CN A2004800274716 A CNA2004800274716 A CN A2004800274716A CN 200480027471 A CN200480027471 A CN 200480027471A CN 1856310 A CN1856310 A CN 1856310A
Authority
CN
China
Prior art keywords
alkyl
aryl
perhaps
atom
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800274716A
Other languages
English (en)
Chinese (zh)
Inventor
B·W·特洛特
R·伊萨克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CN1856310A publication Critical patent/CN1856310A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2004800274716A 2003-09-23 2004-09-17 喹唑啉钾通道抑制剂 Pending CN1856310A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50513903P 2003-09-23 2003-09-23
US60/505,139 2003-09-23

Publications (1)

Publication Number Publication Date
CN1856310A true CN1856310A (zh) 2006-11-01

Family

ID=34392984

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800274716A Pending CN1856310A (zh) 2003-09-23 2004-09-17 喹唑啉钾通道抑制剂

Country Status (8)

Country Link
US (1) US7906521B2 (cg-RX-API-DMAC7.html)
EP (1) EP1667685B1 (cg-RX-API-DMAC7.html)
JP (1) JP4719681B2 (cg-RX-API-DMAC7.html)
CN (1) CN1856310A (cg-RX-API-DMAC7.html)
AT (1) ATE549024T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004275718B2 (cg-RX-API-DMAC7.html)
CA (1) CA2539476C (cg-RX-API-DMAC7.html)
WO (1) WO2005030217A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130730A (zh) * 2011-11-24 2013-06-05 南开大学 新型喹唑啉类衍生物及其制备方法、抗hiv活性和抗tmv活性

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0416730D0 (en) 2004-07-27 2004-09-01 Novartis Ag Organic compounds
CA2575003C (en) 2004-07-29 2010-02-16 Merck & Co., Inc. Potassium channel inhibitors
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
BRPI0608343A2 (pt) * 2005-03-09 2016-10-04 Merck & Co Inc composto, composição farmacêutica, e, métodos para tratamento ou controle de uma doença ou condição, para intensificação da qualidade do sono, para aumento de sono rem e do sono de onda lenta, para diminuição da fragmentação de padrões do sono, para intensificação de cognição, para aumento da retenção de memória, e, para tratamento, controle, melhora ou redução do risco de esquizofrenia em um paciente mamífero em necessidade destes
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007098386A1 (en) * 2006-02-17 2007-08-30 Janssen Pharmaceutica N.V. Pyrazolylquinazolinones as potassium channel openers
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
WO2008112320A1 (en) * 2007-03-15 2008-09-18 The Trustees Of The University Of Pennsylvania Inhibition of ion channel function
CA2692783A1 (en) * 2007-07-10 2009-01-15 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
CN101654441B (zh) * 2008-08-19 2012-10-03 信谊药厂 抗凝化合物、组合物及其用途
WO2010088195A1 (en) * 2009-01-30 2010-08-05 Boehringer Ingelheim International Gmbh Azaquinazolinediones useful as chymase inhibitors
PT2473487T (pt) 2009-09-03 2017-01-04 Bristol Myers Squibb Co Quinazolinas como inibidores dos canais iónicos de potássio
HUE041418T2 (hu) * 2013-08-29 2019-05-28 Kyoto Pharma Ind Aromás vegyületek és alkalmazásuk csont metabolizmushoz kapcsolódó rendellenességek kezelésére
EP3043790B1 (en) 2013-09-11 2021-05-26 The Administrators of the Tulane Educational Fund Novel anthranilic amides and the use thereof
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1311573A (en) 1970-04-27 1973-03-28 Hisamitsu Pharmaceutical Co Quinazolinedione derivatives
GB1491510A (en) * 1973-12-14 1977-11-09 Hisamitsu Pharmaceutical Co 1-nitrophenylquinazoline-2,4(1h,3h)-diones
JPS6020387B2 (ja) * 1975-12-26 1985-05-21 久光製薬株式会社 新規なキナゾリン誘導体の製造法
LU74369A1 (cg-RX-API-DMAC7.html) 1976-02-18 1977-09-12
US5155110A (en) * 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
ATE178210T1 (de) * 1992-09-14 1999-04-15 Forssmann Wolf Georg Prof Dr Neue verwendung von inhibitoren der phosphodiesterase iv
HUT76640A (en) * 1995-08-17 1997-10-28 Chinoin Gyogyszer Es Vegyeszet Compounds of pharmaceutical activity cyclic amide derivatives, pharmaceutical compositions containing them, process for producing them and their use
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6037345A (en) * 1998-01-13 2000-03-14 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazolinedione and pyridopyrimidinedione derivatives
US6870055B2 (en) 2000-09-20 2005-03-22 Merck & Co., Inc. Isoquinolinone potassium channels inhibitors
CN1988907B (zh) 2004-06-01 2010-12-22 弗吉尼亚大学专利基金会 癌瘤及血管生成的双重小分子抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130730A (zh) * 2011-11-24 2013-06-05 南开大学 新型喹唑啉类衍生物及其制备方法、抗hiv活性和抗tmv活性
CN103130730B (zh) * 2011-11-24 2015-04-08 南开大学 喹唑啉类衍生物及其制备方法、抗hiv活性和抗tmv活性

Also Published As

Publication number Publication date
CA2539476A1 (en) 2005-04-07
US20070054894A1 (en) 2007-03-08
JP4719681B2 (ja) 2011-07-06
JP2007506742A (ja) 2007-03-22
WO2005030217A1 (en) 2005-04-07
CA2539476C (en) 2011-04-19
AU2004275718A1 (en) 2005-04-07
EP1667685B1 (en) 2012-03-14
EP1667685A4 (en) 2009-04-29
US7906521B2 (en) 2011-03-15
EP1667685A1 (en) 2006-06-14
AU2004275718B2 (en) 2008-02-07
ATE549024T1 (de) 2012-03-15

Similar Documents

Publication Publication Date Title
CN1856476A (zh) 异喹啉酮钾通道抑制剂
CN1856474A (zh) 异喹啉钾通道抑制剂
CN1856307A (zh) 喹啉钾通道抑制剂
CN1856310A (zh) 喹唑啉钾通道抑制剂
CN1102580C (zh) 芳基乙烯基磺酰胺衍生物及其医药组合物
CN1856475A (zh) 异喹啉钾通道抑制剂
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
CN1993347A (zh) 钾通道抑制剂
CN1474810A (zh) 取代脲,神经肽yy5受体拮抗剂
CN1856473A (zh) 异喹啉酮钾通道抑制剂
CN1351497A (zh) 用作山梨醇脱氢酶抑制剂的氨基嘧啶类化合物
CN1102648A (zh) 取代的单-和双-吡啶基甲基吡啶酮类化合物
CN1382136A (zh) 作为nos抑制剂的n－杂环衍生物
HK1040712A1 (en) Substituted pyrazole derivatives condensed with six-membered heterocyclic rings
CN1441783A (zh) 含二氰基吡啶衍生物的药物
CN1370152A (zh) 5－氰基－2－氨基嘧啶衍生物
CN1856477A (zh) 异喹啉钾通道抑制剂
CN1768054A (zh) 环状脲衍生物、其制备方法以及作为激酶抑制剂的药物用途
CN101031559A (zh) 氨基环脲衍生物和其制法及作为激酶抑制剂的医药用途
CN1639119A (zh) 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
CN1149051A (zh) 用作α1-肾上腺素能受体拮抗剂的嘧啶二酮、嘧啶三酮、三嗪二酮、四氢喹唑啉二酮衍生物
CN101039914A (zh) 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物
CN101048412A (zh) 哌啶基氨基－噻吩并[2,3－d]嘧啶化合物
CN1761671A (zh) 用作PDE7抑制剂的4－氨基噻吩并[2,3－d]嘧啶－6－甲腈衍生物
CN1684951A (zh) 新的嘧啶胺衍生物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication